Top

Published in:

Open Access 01-12-2008 | Review Paper

Regulation of Tumor Progression by Extracellular Galectin-3

Authors: Pratima Nangia-Makker, Vitaly Balan, Avraham Raz

Published in: Cancer Microenvironment | Issue 1/2008

Abstract

The relationship between a tumor cell and its microenvironment is bi-directional. The proteins expressed by the tumor cells alter the signatures on the seemingly normal stromal cells within the microenvironment, while the tumor cell signatures reflect the changes that occur as these cells interact with the host microenvironment. Galectin-3 is a carbohydrate-binding protein that is over-expressed in a variety of tumors and immune cells in response to various stimuli. Ever since its discovery, it has been associated with cell and extracellular matrix interactions. However, in the last decade, an extensive accumulation of data has changed the perspective of this multifunctional protein. The unique structure of this protein, consisting of a carbohydrate-binding domain and a matrix metalloproteinase cleavable domain, enables it to interact with a plethora of ligands in a carbohydrate-dependent or independent manner. It is now becoming evident that galectin-3 is involved with a variety of extracellular functions like cell adhesion, migration, invasion, angiogenesis, immune functions, apoptosis and endocytosis. Galectin-3 is a substrate for matrix metalloproteinases and its cleavage plays an important role in tumor progression and can be used as a surrogate diagnostic marker for in vivo MMP activity.

Dumic J, Dabelic S, Flogel M (2006) Galectin-3: an open-ended story. Biochim Biophys Acta 1760:616–635PubMed

Van den Brule FA, Fernandez PL, Buicu C et al (1997) Differential expression of galectin-1 and galectin-3 during first trimester human embryogenesis. Dev Dyn 209:399–405PubMed

Fowlis D, Colnot C, Ripoche MA et al (1995) Galectin-3 is expressed in the notochord, developing bones, and skin of the postimplantation mouse embryo. Dev Dyn 203:241–251PubMed

Davidson PJ, Li SY, Lohse AG et al (2006) Transport of galectin-3 between the nucleus and cytoplasm. I. Conditions and signals for nuclear import. Glycobiology 16:602–611PubMed

Li SY, Davidson PJ, Lin NY et al (2006) Transport of galectin-3 between the nucleus and cytoplasm. II. Identification of the signal for nuclear export. Glycobiology 16:612–622PubMed

Davidson PJ, Davis MJ, Patterson RJ et al (2002) Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 12:329–337PubMed

van den Brule FA, Waltregny D, Liu FT et al (2000) Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 89:361–367PubMed

Yoshii T, Fukumori T, Honjo Y et al (2002) Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 277:6852–6857PubMed

Yu F, Finley RL Jr., Raz A et al (2002) Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 277:15819–15827PubMed

10.

Shekhar MP, Nangia-Makker P, Tait L et al (2004) Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial–endothelial interactions. Am J Pathol 165:1931–1941PubMed

11.

Moisa A, Fritz P, Eck A et al (2007) Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. Anticancer Res 27:2131–2139PubMed

12.

Sanjuan X, Fernandez PL, Castells A et al (1997) Differential expression of galectin 3 and galectin 1 in colorectal cancer progression [see comments]. Gastroenterology 113:1906–1915PubMed

13.

Califice S, Castronovo V, Van Den Brule F (2004) Galectin-3 and cancer (Review). Int J Oncol 25:983–992PubMed

14.

Honjo Y, Inohara H, Akahani S et al (2000) Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 6:4635–4640PubMed

15.

Hughes RC (1999) Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1473:172–185PubMed

16.

Nickel W (2005) Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells. Traffic 6:607–614PubMed

17.

Gong HC, Honjo Y, Nangia-Makker P et al (1999) The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 59:6239–6245PubMed

18.

Lukyanov P, Furtak V, Ochieng J (2005) Galectin-3 interacts with membrane lipids and penetrates the lipid bilayer. Biochem Biophys Res Commun 338:1031–1036PubMed

19.

Sato S, Hughes RC (1994) Control of Mac-2 surface expression on murine macrophage cell lines. Eur J Immunol 24:216–221PubMed

20.

Lindstedt R, Apodaca G, Barondes SH et al (1993) Apical secretion of a cytosolic protein by Madin–Darby canine kidney cells. Evidence for polarized release of an endogenous lectin by a nonclassical secretory pathway. J Biol Chem 268:11750–11757PubMed

21.

Sato S, Burdett I, Hughes RC (1993) Secretion of the baby hamster kidney 30-kDa galactose-binding lectin from polarized and nonpolarized cells: a pathway independent of the endoplasmic reticulum-Golgi complex. Exp Cell Res 207:8–18PubMed

22.

Mehul B, Hughes RC (1997) Plasma membrane targeting, vesicular budding and release of galectin 3 from the cytoplasm of mammalian cells during secretion. J Cell Sci 110 (Pt 10):1169–1178PubMed

23.

Sato S, Hughes RC (1994) Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. J Biol Chem 269:4424–4430PubMed

24.

Thery C, Boussac M, Veron P et al (2001) Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 166:7309–7318PubMed

25.

Baptiste TA, James A, Saria M et al (2007) Mechano-transduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extracellular functions of the lectin. Exp Cell Res 313:652–664PubMed

26.

Zhu WQ, Ochieng J (2001) Rapid release of intracellular galectin-3 from breast carcinoma cells by fetuin. Cancer Res 61:1869–1873PubMed

27.

Agrwal N, Sun Q, Wang SY et al (1993) Carbohydrate-binding protein 35. I. Properties of the recombinant polypeptide and the individuality of the domains. J Biol Chem 268:14932–14939PubMed

28.

Umemoto K, Leffler H, Venot A et al (2003) Conformational differences in liganded and unliganded states of galectin-3. Biochemistry 42:3688–3695PubMed

29.

Mazurek N, Conklin J, Byrd JC et al (2000) Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligands. J Biol Chem 275:36311–36315PubMed

30.

Kuwabara I, Liu FT (1996) Galectin-3 promotes adhesion of human neutrophils to laminin. J Immunol 156:3939–3944PubMed

31.

van den Brule FA, Buicu C, Sobel ME et al (1995) Galectin-3, a laminin binding protein, fails to modulate adhesion of human melanoma cells to laminin. Neoplasma 42:215–219PubMed

32.

Sato S, Hughes RC (1992) Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J Biol Chem 267:6983–6990PubMed

33.

Hikita C, Vijayakumar S, Takito J et al (2000) Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin 3. J Cell Biol 151:1235–1246PubMed

34.

Ochieng J, Warfield P, Green-Jarvis B et al (1999) Galectin-3 regulates the adhesive interaction between breast carcinoma cells and elastin. J Cell Biochem 75:505–514PubMed

35.

Probstmeier R, Montag D, Schachner M (1995) Galectin-3, a beta-galactoside-binding animal lectin, binds to neural recognition molecules. J Neurochem 64:2465–2472PubMedCrossRef

36.

Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun 246:788–791PubMed

37.

Matarrese P, Fusco O, Tinari N et al (2000) Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85:545–554PubMed

38.

Raz A, Zhu DG, Hogan V et al (1990) Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer 46:871–877PubMed

39.

Dong S, Hughes RC (1997) Macrophage surface glycoproteins binding to galectin-3 (Mac-2-antigen). Glycoconj J 14:267–274PubMed

40.

Ohannesian DW, Lotan D, Thomas P et al (1995) Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 55:2191–2199PubMed

41.

Bresalier RS, Byrd JC, Wang L et al (1996) Colon cancer mucin: a new ligand for the beta-galactoside-binding protein galectin-3. Cancer Res 56:4354–4357PubMed

42.

Warfield PR, Makker PN, Raz A et al (1997) Adhesion of human breast carcinoma to extracellular matrix proteins is modulated by galectin-3. Invasion Metastasis 17:101–112PubMed

43.

Furtak V, Hatcher F, Ochieng J (2001) Galectin-3 mediates the endocytosis of beta-1 integrins by breast carcinoma cells. Biochem Biophys Res Commun 289:845–850PubMed

44.

Ochieng J, Gerold M, Raz A (1992) Dichotomy in the laminin-binding properties of soluble and membrane-bound human galactoside-binding protein. Biochem Biophys Res Commun 186:1674–1680PubMed

45.

Woo HJ, Lotz MM, Jung JU et al (1991) Carbohydrate-binding protein 35 (Mac-2), a laminin-binding lectin, forms functional dimers using cysteine 186. J Biol Chem 266:18419–18422PubMed

46.

Knibbs RN, Agrwal N, Wang JL et al (1993) Carbohydrate-binding protein 35. II. Analysis of the interaction of the recombinant polypeptide with saccharides. J Biol Chem 268:14940–14947PubMed

47.

Yang RY, Hill PN, Hsu DK et al (1998) Role of the carboxyl-terminal lectin domain in self-association of galectin-3. Biochemistry 37:4086–4092PubMed

48.

Ahmad N, Gabius HJ, Andre S et al (2004) Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 279:10841–10847PubMed

49.

Inohara H, Akahani S, Koths K et al (1996) Interactions between galectin-3 and Mac-2-binding protein mediate cell–cell adhesion. Cancer Res 56:4530–4534PubMed

50.

Glinsky VV, Glinsky GV, Rittenhouse-Olson K et al (2001) The role of Thomsen–Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 61:4851–4857PubMed

51.

Glinsky VV, Huflejt ME, Glinsky GV et al (2000) Effects of Thomsen–Friedenreich antigen-specific peptide P-30 on beta-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res 60:2584–2588PubMed

52.

Grassadonia A, Tinari N, Iurisci I et al (2004) 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 19:551–556PubMed

53.

Hughes RC (2001) Galectins as modulators of cell adhesion. Biochimie 83:667–676PubMed

54.

Nangia-Makker P, Honjo Y, Sarvis R et al (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156:899–909PubMed

55.

Lehr JE, Pienta KJ (1998) Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line [see comments]. J Natl Cancer Inst 90:118–123PubMed

56.

Khaldoyanidi SK, Glinsky VV, Sikora L et al (2003) MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen–Friedenreich antigen–galectin-3 interactions. J Biol Chem 278:4127–4134PubMed

57.

Gil CD, La M, Perretti M et al (2006) Interaction of human neutrophils with endothelial cells regulates the expression of endogenous proteins annexin 1, galectin-1 and galectin-3. Cell Biol Int 30:338–344PubMed

58.

Krishnan V, Bane SM, Kawle PD et al (2005) Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin Exp Metastasis 22:11–24PubMed

59.

Inohara H, Raz A (1994) Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 11:527–532PubMed

60.

Nangia-Makker P, Hogan V, Honjo Y et al (2002) Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94:1854–1862PubMed

61.

Zou J, Glinsky VV, Landon LA et al (2005) Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 26:309–318PubMed

62.

Fukushi J, Makagiansar IT, Stallcup WB (2004) NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell 15:3580–3590PubMed

63.

Sano H, Hsu DK, Yu L et al (2000) Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 165:2156–2164PubMed

64.

Camby I, Belot N, Rorive S et al (2001) Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 11:12–26PubMedCrossRef

65.

Savino W, Mendes-Da-Cruz DA, Smaniotto S et al (2004) Molecular mechanisms governing thymocyte migration: combined role of chemokines and extracellular matrix. J Leukoc Biol 75:951–961PubMed

66.

O'Driscoll L, Linehan R, Liang YH et al (2002) Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Res 22:3117–3125PubMed

67.

Lagana A, Goetz JG, Cheung P et al (2006) Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol Cell Biol 26:3181–3193PubMed

68.

Hittelet A, Camby I, Nagy N et al (2003) Binding sites for Lewis antigens are expressed by human colon cancer cells and negatively affect their migration. Lab Invest 83:777–787PubMed

69.

Debray C, Vereecken P, Belot N et al (2004) Multifaceted role of galectin-3 on human glioblastoma cell motility. Biochem Biophys Res Commun 325:1393–1398PubMed

70.

Nangia-Makker P, Ochieng J, Christman JK et al (1993) Regulation of the expression of galactoside-binding lectin during human monocytic differentiation. Cancer Res 53:5033–5037PubMed

71.

Jeng KC, Frigeri LG, Liu FT (1994) An endogenous lectin, galectin-3 (epsilon BP/Mac-2), potentiates IL-1 production by human monocytes. Immunol Lett 42:113–116PubMed

72.

Liu FT, Hsu DK, Zuberi RI et al (1995) Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol 147:1016–1028PubMed

73.

Yamaoka A, Kuwabara I, Frigeri LG et al (1995) A human lectin, galectin-3 (epsilon bp/Mac-2), stimulates superoxide production by neutrophils. J Immunol 154:3479–3487PubMed

74.

Almkvist J, Faldt J, Dahlgren C et al (2001) Lipopolysaccharide-induced gelatinase granule mobilization primes neutrophils for activation by galectin-3 and formylmethionyl-Leu-Phe. Infect Immun 69:832–837PubMed

75.

Feuk-Lagerstedt E, Jordan ET, Leffler H et al (1999) Identification of CD66a and CD66b as the major galectin-3 receptor candidates in human neutrophils. J Immunol 163:5592–5598PubMed

76.

Fernandez GC, Ilarregui JM, Rubel CJ et al (2005) Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alternative MAPK pathways. Glycobiology 15:519–527PubMed

77.

Hsu DK, Hammes SR, Kuwabara I et al (1996) Human T lymphotropic virus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3. Am J Pathol 148:1661–1670PubMed

78.

Kimata H (2002) Enhancement of IgE production in B cells by neutrophils via galectin-3 in IgE-associated atopic eczema/dermatitis syndrome. Int Arch Allergy Immunol 128:168–170PubMed

79.

Sharma UC, Pokharel S, van Brakel TJ et al (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121–3128PubMed

80.

Neidhart M, Zaucke F, von Knoch R et al (2005) Galectin-3 is induced in rheumatoid arthritis synovial fibroblasts after adhesion to cartilage oligomeric matrix protein. Ann Rheum Dis 64:419–424PubMed

81.

Dennis JW, Pawling J, Cheung P et al (2002) UDP-N-acetylglucosamine:alpha-6-D-mannoside beta1,6 N-acetylglucosaminyltransferase V (Mgat5) deficient mice. Biochim Biophys Acta 1573:414–422PubMed

82.

Demetriou M, Granovsky M, Quaggin S et al (2001) Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409:733–739PubMed

83.

Suliman A, Lam A, Datta R et al (2001) Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 20:2122–2133PubMed

84.

Liu FT, Patterson RJ, Wang JL (2002) Intracellular functions of galectins. Biochim Biophys Acta 1572:263–273PubMed

85.

Yang RY, Hsu DK, Liu FT (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 93:6737–6742PubMed

86.

Akahani S, Nangia-Makker P, Inohara H et al (1997) Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 57:5272–5276PubMed

87.

Hanada M, Aime-Sempe C, Sato T et al (1995) Structure–function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem 270:11962–11969PubMed

88.

Fukumori T, Takenaka Y, Yoshii T et al (2003) CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 63:8302–8311PubMed

89.

Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281:1305–1308PubMed

90.

Schulze-Osthoff K, Ferrari D, Los M et al (1998) Apoptosis signaling by death receptors. Eur J Biochem 254:439–459PubMed

91.

Scaffidi C, Fulda S, Srinivasan A et al (1998) Two CD95 (APO-1/Fas) signaling pathways. Embo J 17:1675–1687PubMed

92.

Nagata S (2000) Apoptotic DNA fragmentation. Exp Cell Res 256:12–18PubMed

93.

Peter ME, Krammer PH (1998) Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol 10:545–551PubMed

94.

Peter ME, Krammer PH (2003) The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10:26–35PubMed

95.

Fukumori T, Takenaka Y, Oka N et al (2004) Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res 64:3376–3379PubMed

96.

Lee YJ, Song YK, Song JJ et al (2003) Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Exp Cell Res 288:21–34PubMed

97.

Mazurek N, Sun YJ, Liu KF et al (2007) Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells. J Biol Chem 282:21337–21348PubMed

98.

Rabinovich GA, Cumashi A, Bianco GA et al (2006) Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 16:210–220PubMed

99.

Hsu DK, Zuberi RI, Liu FT (1992) Biochemical and biophysical characterization of human recombinant IgE- binding protein, an S-type animal lectin. J Biol Chem 267:14167–14174PubMed

100.

Ochieng J, Green B, Evans S et al (1998) Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochim Biophys Acta 1379:97–106PubMed

101.

Raz A, Pazerini G, Carmi P (1989) Identification of the metastasis-associated, galactoside-binding lectin as a chimeric gene product with homology to an IgE-binding protein. Cancer Res 49:3489–3493PubMed

102.

Ochieng J, Fridman R, Nangia-Makker P et al (1994) Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 33:14109–14114PubMed

103.

Nagase H, Woessner JF, Jr. (1999) Matrix metalloproteinases. J Biol Chem 274:21491–21494PubMed

104.

John CM, Leffler H, Kahl-Knutsson B et al (2003) Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 9:2374–2383PubMed

105.

Nangia-Makker P, Raz T, Tait L, Hogan V, Fridman R, Raz A (2007) Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancer. Cancer Res 67:11760–11768PubMed

Title: Regulation of Tumor Progression by Extracellular Galectin-3
Authors: Pratima Nangia-Makker
Vitaly Balan
Avraham Raz
Publication date: 01-12-2008
Publisher: Springer Netherlands
Published in: Cancer Microenvironment / Issue 1/2008
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-008-0003-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Matricellular Proteins Produced by Melanocytes and Melanomas: In Search for Functions

Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis

The Prometastatic Microenvironment of the Liver

Bone Marrow Microenvironment and Tumor Progression

Abnormal Growth Factor/Cytokine Network in Gastric Cancer

Systems Biology: A Therapeutic Target for Tumor Therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer